PPAP

PPAP, chemically (-)-1-phenyl-2-propylaminopentane, is a synthetic compound developed by the Hungarian pharmacologist Joseph Knoll and colleagues at Semmelweis University in Budapest ^[1][7]. It is a structural analogue of deprenyl (selegiline), Knoll's better-known creation, and both are derivatives of phenylethylamine related to methamphetamine and amphetamine; PPAP, however, was deliberately designed to be free of monoamine oxidase (MAO) inhibitory activity, isolating a different property ^[1][3]. That property is what Knoll named the 'catecholaminergic activity enhancer' or CAE effect, and PPAP became the prototype clean CAE substance used to define and study the enhancer concept ^[1][7].

The CAE effect describes a form of neuronal activation distinct from the actions of classical stimulants. Whereas amphetamine and methamphetamine work chiefly by releasing catecholamines from their storage sites, PPAP enhances the impulse-propagation-mediated release of transmitters, meaning it makes catecholaminergic neurons release more dopamine and noradrenaline when they fire, without itself acting as a releasing agent or an MAO inhibitor ^[1][2]. Knoll proposed that endogenous trace amines such as beta-phenylethylamine and tryptamine are the body's natural enhancer substances, and that synthetic CAE compounds like PPAP mimic this regulation ^[5][7]. Research using PPAP helped establish that the enhancer effect of deprenyl is unrelated to its inhibition of MAO-B ^[3][7].

PPAP was subsequently used as the chemical starting point for developing more potent and selective enhancers; by modifying its aromatic ring, Knoll's group synthesized 65 new compounds and selected (-)BPAP, a tryptamine-derived enhancer far stronger than either PPAP or deprenyl ^[5]. The bulk of the published evidence on PPAP comes from this single research group and consists of animal and in vitro pharmacology; PPAP itself has not been developed into an approved medicine and has no established human clinical literature, and selegiline remains the only clinically used enhancer drug ^[6][7]. Today PPAP is encountered mainly as a research chemical and nootropic, typically supplied as a powder, and it is not approved for medical use or as a dietary supplement ^[7].

NO HUMAN SAFETY DATA OF ANY KIND. No pharmacokinetics, no tolerability, no overdose or poisoning reports, no drug-interaction studies. Any statement about how PPAP behaves in people is unsourced extrapolation.

Preclinical signals: PPAP produced substantially less stereotyped behaviour than amphetamine or methamphetamine and improved performance across a broad dose range rather than amphetamine's narrow one, with locomotor suppression only at very high doses near 50 mg/kg (PMID 1356324). A single weaning-age dose moderately raised serotonin in rat monocytes, granulocytes and mast cells three weeks later, an effect deprenyl did not share and whose significance is unknown (PMID 15584092).

Abuse liability is genuinely unsettled, and the conflict should be stated rather than resolved. The design intent was low abuse potential precisely because PPAP does not release catecholamines. Against that, the 2026 independent profiling found PPAP is a potent DAT uptake inhibitor with the highest DAT/SERT ratio of all amphetamine analogues tested, and those authors treat high DAT selectivity as a marker of abuse potential (PMID 42449077). A DAT blocker roughly as potent as amphetamine is not obviously benign.

Interactions: none studied. Because PPAP does not inhibit MAO, the tyramine and serotonin-syndrome cautions attached to selegiline do not transfer on mechanism grounds; that is reasoning, not evidence. Its DAT and NET inhibition means combination with other stimulants or serotonergic drugs carries a theoretical but untested risk.

Regulatory status: PPAP is not an approved medicine in any jurisdiction and has no marketing authorisation anywhere. It was detected on the European drug market and logged by the EU Early Warning System in 2018 (Table 1, PMID 42449077), so it circulates as a grey-market research chemical.

WADA: PPAP is not named anywhere in the 2026 Prohibited List; the full PDF text was extracted and searched, returning zero hits for PPAP or propylaminopentane. It is nonetheless caught by S6 Stimulants, prohibited IN-COMPETITION, which opens "All stimulants, including all optical isomers, e.g. d- and l- where relevant, are prohibited" and expressly lists both "Phenethylamine and its derivatives" and "Selegiline". Since it is not expressly listed it would be a Specified Substance. Any tested athlete should treat PPAP as banned in competition.

National scheduling could NOT be verified. Claims circulating online that PPAP is UK Class A, Canada Schedule 1, and Swedish-controlled since 2020 could not be confirmed against primary legal texts. The Swedish claim rests on a third-party aggregator rather than Folkhalsomyndigheten or Lakemedelsverket, and "UK Class A" looks doubtful given amfetamine itself is Class B. Generic amphetamine-analogue provisions plausibly capture it in some countries, and the UK Psychoactive Substances Act 2016 would cover it regardless. Verify against local law before asserting anything specific.

PPAP, chemically 1-phenyl-2-propylaminopentane, was created by the Hungarian pharmacologist Joseph Knoll and his colleagues at Semmelweis University in Budapest, the same laboratory that had earlier given the world selegiline (deprenyl).

Knoll designed PPAP deliberately as a deprenyl analogue stripped of monoamine oxidase inhibitory activity, so that it could serve as a clean chemical tool to prove that the so-called catecholaminergic activity enhancer effect exists independently of MAO inhibition.

In a landmark 1996 study in Life Sciences, Knoll and coworkers demonstrated that both deprenyl and PPAP act primarily as stimulants of the coupling between a neuron's action potential and its release of transmitter, an effect unrelated to MAO inhibition, receptor blockade, reuptake inhibition, or direct catecholamine release.

PPAP thus became the prototype of the enhancer class and established the conceptual foundation for its far more potent successor, BPAP. The compound has remained a research substance used to characterize enhancer pharmacology, and it has not undergone formal clinical development in humans.

PPAP holds an honored place in neuropharmacology as the proof-of-concept molecule for an entire drug category, the catecholaminergic activity enhancers, which promise to raise dopaminergic and noradrenergic tone without the forced neurotransmitter release and subsequent depletion that characterize amphetamines. Researchers value it precisely because it is clean: by lacking MAO inhibition and reuptake blockade in Knoll's original framing, it isolated the enhancer phenomenon and made it measurable.

The concept it embodies, keeping the aging brain's catecholamine systems running at a higher activity level, continues to inspire work on cognition and neuroprotection. Honesty requires noting that the compelling data on PPAP come almost entirely from animal and laboratory studies; its effect size, pharmacokinetics, and safety in humans have not been characterized in clinical trials. It is best appreciated as a foundational and scientifically significant compound rather than a validated human therapeutic.